Yes, Qulipta Is a Daily Pill for Migraine Prevention
Qulipta (atogepant) is an oral tablet taken once daily to prevent episodic migraines in adults. It's a calcitonin gene-related peptide (CGRP) receptor antagonist designed for long-term use, unlike acute treatments like triptans. The FDA approved it in 2021 for this purpose.[1]
How Do You Take Qulipta?
Patients take one 60 mg tablet daily, with or without food, at the same time each day. No dose adjustments are needed for mild to moderate liver or kidney issues, but it's not recommended for severe cases. Treatment starts working within weeks, with full effects often seen after 4-12 weeks.[1][2]
What Makes Qulipta Different from Acute Migraine Pills?
Qulipta prevents migraines rather than treating attacks after they start. Acute options like Ubrelvy (ubrogepant) or Nurtec (rimegepant) are taken as needed during a migraine and can be used up to 8 times monthly. Qulipta has no such limit but isn't for immediate relief.[1]
Common Side Effects and Who Should Avoid It?
Nausea (10-12%), constipation (8-10%), and fatigue (5-6%) are most reported. Rare risks include allergic reactions or liver enzyme elevations. Avoid if pregnant, breastfeeding, or with severe liver impairment. Interactions occur with strong CYP3A4 inhibitors like ketoconazole.[1][2]
How Does Qulipta Compare to Other Preventive Options?
| Drug | Type | Dosing | Key Notes |
|------|------|--------|-----------|
| Qulipta (atogepant) | Oral CGRP blocker | Daily pill | No injection; nausea common |
| Emgality (galcanezumab) | CGRP antibody | Monthly injection | Injection site reactions |
| Nurtec (rimegepant) ODT | Oral gepant | Every other day | Dual acute/preventive use |
| Topamax (topiramate) | Anticonvulsant | Daily pill | Weight loss, cognitive side effects |
Qulipta offers a pill alternative to injectables, with trials showing 4-5 fewer migraine days monthly versus placebo.[1][3]
Cost and Insurance Coverage
A 30-day supply costs $900-$1,000 without insurance. Most plans cover it with prior authorization, often at $25-$50 copay. AbbVie patient assistance programs reduce costs for eligible uninsured patients.[2]
When Does Qulipta's Patent Expire?
Core patents on atogepant expire around 2032-2035, with formulation patents possibly extending exclusivity. No generics are approved yet; check DrugPatentWatch.com for updates on challenges or Paragraph IV filings.[4]
[1]: FDA Label - Qulipta (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215151s000lbl.pdf)
[2]: AbbVie prescribing information (https://www.qulipta.com/)
[3]: NEJM trial data (https://www.nejm.org/doi/full/10.1056/NEJMoa1917351)
[4]: DrugPatentWatch - Qulipta (https://www.drugpatentwatch.com/p/tradename/QULIPTA)